Share

August 2015; 2 (4) ArticleOpen Access

Hematologic modifications in natalizumab-treated multiple sclerosis patients

An 18-month longitudinal study

Claire Bridel, Yan Beauverd, Kaveh Samii, Patrice H. Lalive
First published June 18, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000123
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1899

Share

Article Information

vol. 2 no. 4 e123
DOI: 
https://doi.org/10.1212/NXI.0000000000000123
PubMed: 
26140281
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received December 22, 2014
  • Accepted in final form March 30, 2015
  • First Published June 18, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Claire Bridel, MD, PhD*,
    2. Yan Beauverd, MD*,
    3. Kaveh Samii, MD and
    4. Patrice H. Lalive, MD
  1. Claire Bridel, MD, PhD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Yan Beauverd, MD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Kaveh Samii, MD and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Patrice H. Lalive, MD
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Clinical Neurosciences (C.B., P.H.L.), Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis; Department of Hematology (Y.B., K.S.); and Department of Genetics and Laboratory Medicine (P.H.L.), Laboratory Medicine Service, University Hospital of Geneva, Switzerland.
  1. Correspondence to Prof. Lalive: patrice.lalive{at}hcuge.ch

Article usage

Article usage: June 2015 to November 2023

AbstractFullPdfSource
Jun 201514015910Highwire
Jul 201517812821Highwire
Jul 201507551pmc
Aug 20153549558Highwire
Aug 201502519pmc
Sep 2015602014Highwire
Sep 201502616pmc
Oct 201546812Highwire
Oct 20150229pmc
Nov 20152465Highwire
Nov 201501812pmc
Dec 20153533Highwire
Dec 201502311pmc
Jan 2016451011Highwire
Jan 2016094pmc
Feb 201632910Highwire
Feb 20160173pmc
Mar 20163657Highwire
Mar 201601912pmc
Apr 201632912Highwire
Apr 20160215pmc
May 20161221Highwire
May 20160192pmc
Jun 201639516Highwire
Jun 201603619pmc
Jul 20162441Highwire
Jul 20160207pmc
Aug 2016811Highwire
Aug 201604211pmc
Sep 20161416Highwire
Sep 201604713pmc
Oct 201613156Highwire
Oct 201604812pmc
Nov 20161486Highwire
Nov 20160473pmc
Dec 2016443Highwire
Dec 20160579pmc
Jan 20171323Highwire
Jan 20170727pmc
Feb 2017672Highwire
Feb 20170655pmc
Mar 20171532Highwire
Mar 20170806pmc
Apr 20171961Highwire
Apr 201776070pmc
May 2017744Highwire
May 201766669pmc
Jun 2017532Highwire
Jun 2017138195pmc
Jul 2017100Highwire
Jul 201757889pmc
Aug 20171152Highwire
Aug 2017186110pmc
Sep 2017320Highwire
Sep 20176104117pmc
Oct 2017524Highwire
Oct 201786971pmc
Nov 2017913Highwire
Nov 201738795pmc
Dec 2017171Highwire
Jan 20180103Highwire
Feb 20181102Highwire
Mar 20180120Highwire
Apr 20180111Highwire
Apr 201848493pmc
May 20181473Highwire
Jun 20182234Highwire
Jun 201856976pmc
Jul 20180193Highwire
Aug 20181112Highwire
Aug 2018489103pmc
Sep 20180151Highwire
Oct 20181204Highwire
Nov 20181150Highwire
Dec 20183196Highwire
Jan 20192190Highwire
Feb 20194153Highwire
Mar 2019284Highwire
Apr 2019164Highwire
May 20195196Highwire
Jun 20192117Highwire
Jul 20193106Highwire
Aug 2019174Highwire
Sep 2019165Highwire
Oct 20195137Highwire
Nov 20192155Highwire
Dec 20193287Highwire
Jan 20202113Highwire
Feb 20200128Highwire
Mar 2020267Highwire
Apr 2020066Highwire
May 20201205Highwire
Jun 20201114Highwire
Jul 2020193Highwire
Aug 20203155Highwire
Sep 20208227Highwire
Oct 20200423Highwire
Nov 20201148Highwire
Dec 202021210Highwire
Jan 202112112Highwire
Feb 20212237Highwire
Mar 202121410Highwire
Apr 20213193Highwire
May 2021395Highwire
Jun 20213212Highwire
Jul 202143215Highwire
Aug 20211176Highwire
Sep 2021389Highwire
Oct 202151718Highwire
Nov 202122116Highwire
Dec 20211155Highwire
Jan 20221611Highwire
Feb 20220235Highwire
Mar 20221318Highwire
Apr 2022272Highwire
May 20221218Highwire
Jun 20223189Highwire
Jul 20225167Highwire
Aug 20225276Highwire
Sep 202262510Highwire
Oct 202222210Highwire
Nov 202275317Highwire
Dec 2022115111Highwire
Jan 202364115Highwire
Feb 20234288Highwire
Mar 20231137Highwire
Apr 20231129Highwire
May 20232206Highwire
Jun 2023394Highwire
Jul 20231127Highwire
Aug 202342211Highwire
Sep 20233137Highwire
Oct 20234122Highwire
Nov 2023044Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles